Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncometabolite Tinkers with Genome Folding, Boosting Oncogene Expression.

Trends in molecular medicine - 1 Mar 2016

Ing-Simmons Elizabeth, Merkenschlager Matthias

Abstract excerpt

A recent article makes a compelling case for a new mechanism by which heterozygous mutations in isocitrate dehydrogenases (IDH1/2)--implicated in cancer--undermine gene regulation. 2-Hydroxyglutarate (2HG) produced by mutant IDH alters the binding of the chromosomal organizer protein CTCF, disrupting the spatial and regulatory organization of the genome.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CTCF gene
Share to Gene Expression Regulation, Neoplastic
Share to IDH1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Oncogenes

Source

Identifiers

PMID: 26856236
DOI: 10.1016/j.molmed.2016.01.008

Genes

CTCF
IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncometabolite Tinkers with Genome Folding, Boosting Oncogene Expression.PMID 26856236Read ↗

What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.Semantic proximity Read ↗

Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human diseaseSemantic proximity Read ↗

Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies.Semantic proximity Read ↗

The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches.Semantic proximity Read ↗

Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities.Semantic proximity Read ↗

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.Semantic proximity Read ↗

2-Hydroxyglutarate in Cancer Cells.Semantic proximity Read ↗

Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models.Semantic proximity Read ↗

Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting tumor mutation burdenSemantic proximity Read ↗

Beyond Isocitrate Dehydrogenase Mutations: Emerging Mechanisms for the Accumulation of the Oncometabolite 2-Hydroxyglutarate.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.